Olga Kozyreva, MD - Dana-Farber Cancer ...

Dr. Olga Kozyreva, MD

Claim this profile

Dana-Farber Cancer Institute at St. Elizabeth's Medical Center

Studies Prostate Cancer
Studies Hematologic Malignancies
6 reported clinical trials
11 drugs studied

Area of expertise

1Prostate Cancer
Olga Kozyreva, MD has run 2 trials for Prostate Cancer. Some of their research focus areas include:
BRCA1
BRCA2
NTRK1
2Hematologic Malignancies
Olga Kozyreva, MD has run 2 trials for Hematologic Malignancies. Some of their research focus areas include:
Stage IV

Affiliated Hospitals

Image of trial facility.
Dana-Farber Cancer Institute At St. Elizabeth's Medical Center
Image of trial facility.
Steward Saint Elizabeth's Medical Center

Clinical Trials Olga Kozyreva, MD is currently running

Image of trial facility.

SURGE Support Program

for Cancer Trial Enrollment

This trial aims to help underrepresented cancer patients understand and agree to genomic testing by providing a guide, sending text message questions, and showing an informational video. The goal is to make it easier for these patients to access personalized treatments and clinical trials. By addressing their educational and social needs, the intervention supports better decision-making about their care.
Recruiting1 award N/A
Image of trial facility.

Blood Test and Immunotherapy

for Bladder Cancer

This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer from coming back, can be identified by a blood test. Many types of tumors tend to lose cells or release different types of cellular products including their DNA which is referred to as circulating tumor DNA (ctDNA) into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for disease progression or relapse. In this study, a blood test is used to measure ctDNA and see if there is still cancer somewhere in the body after surgery and if giving a treatment will help eliminate the cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and relatlimab, can help the body's immune system to attack the cancer, and can interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine if ctDNA measurement in blood can better identify patients that need additional treatment, if treatment with nivolumab prolongs patients' life and whether the additional immunotherapy treatment with relatlimab extends time without disease progression or prolongs life of urothelial cancer patients who have undergone surgical removal of their bladder, kidney, ureter or urethra.
Recruiting1 award Phase 2 & 310 criteria

More about Olga Kozyreva, MD

Clinical Trial Related6 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Olga Kozyreva, MD has experience with
  • Nivolumab
  • SURGE
  • Bevacizumab
  • Cholecalciferol
  • Fluorouracil
  • Irinotecan

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Olga Kozyreva, MD specialize in?
Is Olga Kozyreva, MD currently recruiting for clinical trials?
Are there any treatments that Olga Kozyreva, MD has studied deeply?
What is the best way to schedule an appointment with Olga Kozyreva, MD?
What is the office address of Olga Kozyreva, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security